Tricor
(Fenofibrate)ApprovedSmall molecule
Fenofibrate is used to lower high triglycerides (a type of fat) in the blood and to increase good cholesterol, helping reduce the risk of heart disease and stroke.[2] Tricor is currently approved and in use across 45 indications[4].[1]
Tricor is one of 686 small molecule programs targeting Insulin resistance. It is currently in Approved.
45
Indications
125
Total Trials
18
Active Trials
685
Competitors
7
FDA Applications
NDA/BLA/ANDA regulatory filings
1
Patents
Pipeline
Status by Indication[4][1]
Indication
Showing 10 of 44 indications
Competition
Competitive Landscape
702 competitors in Breast Cancer
#DrugCompanyPhaseTrials
1Tricor
JJagotec
Approved
Adenocard
AstellasPreclinical
Lexiscan
AstellasPreclinical
Voltaren
NovartisPreclinical
Duragesic
CCephalon
Preclinical
Acupan
YYonsei University
Preclinical
Chantix
PPrism Pharmaceuticals
Preclinical
Nubain
AAultman Health Foundation
Preclinical
Beta Blocker
WWeill Medical College of Cornell University
Preclinical
Recombinant Human Endostatin
PPeking University Third Hospital
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Efficacy and Safety6 trials
Randomized Comparative Efficacy and Safety Study of Intermittent Simvastatin and Fenofibrate in Hemodialysis
Completed·—·Phase 4·NCT02886299·60 enrolled
Show 3 more trials
Efficacy and Safety of Fenofibrate Combined With UDCA in PBC Patients With an Incomplete Biochemical Response to UDCA
Withdrawn·—·Phase 1/2·NCT02965911
Primary Biliary Cholangitis4 trials
Diabetic Retinopathy3 trials
Dyslipidemia3 trials
Heart Disease3 trials
Diet, Exercise, Niacin, and Fenofibrate to Reduce Heart Disease Risk Factors in Individuals With HIV Lipodystrophy or Dyslipidemia
Completed·—·N/A·NCT00246376·221 enrolled
79 more indications
Fed3 trials
Atorvastatin3 trials
Primary Biliary Cirrhosis3 trials
Type 2 Diabetes3 trials
Primary Biliary Cholangitis (PBC)3 trials
Combination Therapy2 trials
Cardiovascular Disease2 trials
Statin2 trials
Familial Hypercholesterolemia2 trials
Type 1 Diabetes2 trials
Fasting Conditions2 trials
Hyperbilirubinemia2 trials
Lip2 trials
Metabolism2 trials
Neonatal Jaundice2 trials
Role of Fenofibrate in Neonatal Jaundice
Completed·—·Phase 4·NCT06451900·75 enrolled
Alcoholic Fatty Liver Disease2 trials
Non-Alcoholic Fatty Liver Disease2 trials
Combined hyperlipidemia1 trial
Humans1 trial
Effectiveness1 trial
Safety and Effectiveness of Fenofibrate and Pravastatin in HIV-Positive Patients With Abnormal Blood Lipids
Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 3·NCT00006412·630 enrolled
ART1 trial
Cardiotoxicity1 trial
Homozygous Familial Hypercholesterolemia1 trial
Endothelial Function1 trial
Mixed Dyslipidemia1 trial
Celecoxib1 trial
Etoposide, Cyclophosphamide, Thalidomide, Celecoxib, and Fenofibrate in Relapsed or Progressive Cancer
Completed·—·Phase 2·NCT00357500·101 enrolled
Polycystic Ovary Syndrome1 trial
Multiple Myeloma1 trial
Biomarkers1 trial
Cholesterol1 trial
Type 2 Diabetes Mellitus1 trial
Simvastatin and Fenofibrate vs Simvastatin Alone in Patients With Type 2 Diabetes Mellitus and Acute Coronary Syndrome
Unknown status·—·Phase 4·NCT02015988·60 enrolled
Tics1 trial
Huntington's Disease1 trial
Acute Coronary Syndrome1 trial
Endothelial Dysfunction1 trial
Effect of a Fibrate and a Statin on Endothelial Dysfunction
Terminated·—·N/A·NCT00491400·28 enrolled
Liver Transplant1 trial
Atherogenic Dyslipidemia1 trial
Safety and Efficacy1 trial
Monotherapy1 trial
COVID-191 trial
Weight loss1 trial
Hyperlipidemia1 trial
Breast Cancer1 trial
Fenofibrate Role in Breast Cancer Patients
Completed·—·N/A·NCT05813145·50 enrolled
Randomized1 trial
Overweight1 trial
Inflammatory Mediators1 trial
Hypertriglyceridemia1 trial
Hepatic Function1 trial
Klinefelter Syndrome1 trial
Albuminuria1 trial
Evaluate the Efficacy of Fenofibrate on Microalbuminuria
Unknown status·—·Phase 4·NCT02314533·200 enrolled
Inflammatory Bowel Diseases1 trial
Jaundice, Neonatal1 trial
Cervical Intraepithelial Neoplasia1 trial
Primary Sclerosing Cholangitis1 trial
Unspecified5 trials
Regulatory
FDA Approval Timeline[5]
Dec 31, 1993
LIPIDIL
NDA NDA019304
Sep 4, 2001
TRICOR
NDA NDA021203
Nov 5, 2004
TRICOR
NDA NDA021656
May 7, 2005
TRIGLIDE
NDA NDA021350
Jan 11, 2006
LIPOFEN
NDA NDA021612
Aug 10, 2007
FENOGLIDE
NDA NDA022118
Oct 18, 2013
ANTARA (MICRONIZED)
NDA NDA021695
Sources
References
- [1]
- [2]MedlinePlus Drug Information — Tricor drug information. U.S. National Library of Medicine, National Institutes of Health.
- [3]
- [4]Open Targets Platform — Drug–disease associations for Fenofibrate. EMBL-EBI & Wellcome Sanger Institute.
- [5]
- [6]FDA Orange Book — Patent and exclusivity data for Tricor. U.S. Food & Drug Administration.
- [7]